Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of 4D Molecular Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001650648.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- FDMT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001650648
- Issuer location
- Emeryville, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of 4D Molecular Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
10%
BIOTECHNOLOGY VALUE FUND L P
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
GOLDMAN SACHS GROUP INC
7.5%
BlackRock, Inc.
6.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
10%
|
$48,852,550
5,247,151 shares
|
+$5,691,163 | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$52,609,747
5,346,519 shares
|
-$4,927,498 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
13D/G
13F
10%+ Owner · Company
|
9.9%
from 13D/G
|
$74,517,236
8,173,211 shares
mixed-class rows
|
— | 09 Dec 2024 |
| GOLDMAN SACHS GROUP INC |
13F
13D/G
Company · THE GOLDMAN SACHS GROUP, INC.
|
7.5%
from 13D/G
|
$56,640,284
4,258,668 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$60,462,583
4,546,059 shares
|
— | 30 Jun 2026 |
| Novo Holdings A/S |
13F
13D/G
Company
|
6.4%
from 13D/G
|
$43,214,067
3,249,178 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5.3%
from 13D/G
|
$38,717,750
2,911,109 shares
|
— | 30 Jun 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
1.5%
|
$2,202,200
677,600 shares
|
-$7,393,006 | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$4,647,473.
Buys
$0
Insiders: 0
Sells
$4,647,473
Insiders: 3
Net
-$4,647,473
Shares: -375,074
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 375,074
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 359,975 | $0 | $4,494,244 | -$4,494,244 |
| 3-6 | 0 | 1,922 | $0 | $19,258 | -$19,258 |
| 6-9 | 0 | 390 | $0 | $3,358 | -$3,358 |
| 9-12 | 0 | 12,787 | $0 | $130,613 | -$130,613 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to 4D Molecular Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
VIKING GLOBAL INVESTORS LP
Net 12M change
-$4,647,472
Latest report
14 Sep 2026
Recent insider transactions for 4D Molecular Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Kirn | FDMT | Common Stock | Sale | -7.06% | $811,004 | $13.90 | -58,333 | 767,486 | 14 Sep 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Sale | -6.35% | $8,176 | $14.00 | -584 | 8,617 | 01 Sep 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 6.78% | 584 | 9,201 | 01 Sep 2026 | Direct | ||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Options Exercise | -16.5% | -584 | 2,959 | 01 Sep 2026 | Direct | ||
| David Kirn | FDMT | Common Stock | Sale | -7.72% | $1,088,273 | $15.75 | -69,076 | 825,819 | 19 Aug 2026 | Direct |
| David Kirn | FDMT | Common Stock | Options Exercise | 5.92% | 50,000 | 894,895 | 19 Aug 2026 | Direct | ||
| David Kirn | FDMT | Stock Option (Right to Buy) | Options Exercise | -18.7% | -50,000 | 217,500 | 19 Aug 2026 | Direct | ||
| Scott Bizily | FDMT | Common Stock | Sale | -16% | $19,947 | $12.20 | -1,635 | 8,617 | 17 Aug 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 19% | 1,635 | 10,252 | 17 Aug 2026 | Direct | ||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Options Exercise | -2.67% | -1,635 | 59,701 | 17 Aug 2026 | Direct | ||
| Scott Bizily | FDMT | Common Stock | Sale | -16% | $19,620 | $12.00 | -1,635 | 8,617 | 13 Aug 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 19% | 1,635 | 10,252 | 13 Aug 2026 | Direct | ||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Options Exercise | -2.6% | -1,635 | 61,336 | 13 Aug 2026 | Direct | ||
| David Kirn | FDMT | Common Stock | Sale | -3.08% | $274,596 | $10.23 | -26,842 | 844,895 | 04 Aug 2026 | Direct |
| David Kirn | FDMT | Common Stock | Sale | -1.4% | $124,722 | $10.05 | -12,415 | 871,737 | 03 Aug 2026 | Direct |
| David Kirn | FDMT | Common Stock | Sale | -1.75% | $189,233 | $12.03 | -15,725 | 884,152 | 10 Jul 2026 | Direct |
| David Kirn | FDMT | Common Stock | Sale | -4.52% | $548,177 | $12.87 | -42,608 | 899,877 | 09 Jul 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Sale | -43.2% | $91,924 | $14.00 | -6,566 | 8,617 | 30 Jun 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 76.2% | 6,566 | 15,183 | 30 Jun 2026 | Direct | ||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Options Exercise | -65% | -6,566 | 3,543 | 30 Jun 2026 | Direct | ||
| Scott Bizily | FDMT | Common Stock | Sale | -53.2% | $117,720 | $12.00 | -9,810 | 8,617 | 23 Jun 2026 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 113.8% | 9,810 | 18,427 | 23 Jun 2026 | Direct | ||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Options Exercise | -13.3% | -9,810 | 63,785 | 23 Jun 2026 | Direct | ||
| David Kirn | FDMT | Common Stock | Sale | -10.8% | $1,200,851 | $10.47 | -114,746 | 942,485 | 22 Jun 2026 | Direct |
| Shawn Cline Tomasello | FDMT | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 17 Jun 2026 | Direct | |||
| Charles Theuer | FDMT | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 17 Jun 2026 | Direct | |||
| Nancy Miller-Rich | FDMT | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 17 Jun 2026 | Direct | |||
| Susannah Gray | FDMT | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 17 Jun 2026 | Direct | |||
| John F. Milligan | FDMT | Stock Option (Right to Buy) | Award | 75,000 | 75,000 | 17 Jun 2026 | Direct | |||
| Glenn Sblendorio | FDMT | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 17 Jun 2026 | Direct | |||
| Jacob Chacko | FDMT | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 17 Jun 2026 | Direct | |||
| David Kirn | FDMT | Common Stock | Sale | -0.18% | $19,258 | $10.02 | -1,922 | 1,057,231 | 01 Jun 2026 | Direct |
| David Kirn | FDMT | Stock Option (Right to Buy) | Award | 750,000 | 750,000 | 25 Mar 2026 | Direct | |||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Award | 217,000 | 217,000 | 25 Mar 2026 | Direct | |||
| Christopher Paul Simms | FDMT | Stock Option (Right to Buy) | Award | 219,000 | 219,000 | 25 Mar 2026 | Direct | |||
| Ashoo Gupta | FDMT | Common Stock | Sale | -0.82% | $3,358 | $8.61 | -390 | 46,914 | 20 Mar 2026 | Direct |
| Ashoo Gupta | FDMT | Common Stock | Options Exercise | 2.35% | 1,086 | 47,224 | 20 Mar 2026 | Direct | ||
| Ashoo Gupta | FDMT | Restricted Stock Units | Options Exercise | -26% | -1,086 | 3,087 | 20 Mar 2026 | Direct | ||
| Glenn Sblendorio | FDMT | Stock Option (Right to Buy) | Award | 45,000 | 45,000 | 05 Jan 2026 | Direct | |||
| Ashoo Gupta | FDMT | Common Stock | Sale | -0.83% | $3,377 | $8.68 | -389 | 46,218 | 20 Dec 2025 | Direct |
| Ashoo Gupta | FDMT | Common Stock | Options Exercise | 2.39% | 1,086 | 46,528 | 20 Dec 2025 | Direct | ||
| Ashoo Gupta | FDMT | Restricted Stock Units | Options Exercise | -24.7% | -1,086 | 3,308 | 20 Dec 2025 | Direct | ||
| Scott Bizily | FDMT | Common Stock | Sale | -31.3% | $17,822 | $10.90 | -1,635 | 3,594 | 16 Dec 2025 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 45.5% | 1,635 | 5,229 | 16 Dec 2025 | Direct | ||
| Scott Bizily | FDMT | Stock Option (Right to Buy) | Options Exercise | -2.17% | -1,635 | 73,595 | 16 Dec 2025 | Direct | ||
| Charles Theuer | FDMT | Common Stock | Options Exercise | 28.8% | 9,333 | 41,684 | 12 Dec 2025 | Direct | ||
| Charles Theuer | FDMT | Stock Option (Right to Buy) | Options Exercise | -100% | -9,333 | 0 | 12 Dec 2025 | Direct | ||
| Kristian Humer | FDMT | Stock Option (Right to Buy) | Award | 480,000 | 480,000 | 09 Dec 2025 | Direct | |||
| Scott Bizily | FDMT | Common Stock | Sale | -31.3% | $17,315 | $10.59 | -1,635 | 3,594 | 17 Nov 2025 | Direct |
| Scott Bizily | FDMT | Common Stock | Options Exercise | 45.5% | 1,635 | 5,229 | 17 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.